Clinical trials: Auto Immune Disorders
Atopic Dermatitis (AD), Autoantibody
Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis
Previous research has shown that some patients with atopic eczema have specific self-reactive antibodies, known as IgE autoantibodies, that react to their own skin cells, referred to as "self-reactive antibodies" or…
- Conditions
- Atopic Dermatitis (AD), Autoantibody, Auto-Immunity, Microbiome, Human
- Trial name
- DIANA (NCT07316465)
- Testing
- Development of atopic dermatitis with/without IgE autoantibodies
- Where
- Belgium
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Autoimmune Diseases
Lymphocyte Sub-populations and Auto Immune Diseases
To determine if artificial intelligence allow to detect lymphocyte subpopulations specific of diseases (such as primary Sjogren' syndrome and systemic lupus erythematosus) among patients with suspicion of autoimmune diseases.
- Trial name
- SPLIT (NCT03901664)
- Where
- France
- Volunteers
- 3,500 people
- Sponsor
- University Hospital, Brest
Hodgkin Disease, Hodgkin Lymphoma
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma
Background: Hodgkins lymphoma (HL) is a highly treatable cancer. However, if HL does not respond to chemotherapy or returns after chemotherapy, further treatments often are not successful.
- Trial name
- NCT01468311
- Testing
- Auto stem cell transplant, BEAM, 111In-daclizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-cell Lymphoma
R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL
Patients initially are randomized into 2 arms: Arm I: R-DA-EPOCH; Arm II: R-CEOP90; Patients who achieved complete remission (CR) or partial remission (PR) after 6 cycles of R-DA-EPOCH (Arm I) or R-CEOP90 (Arm II), continue to…
- Trial name
- NCT03213977
- Testing
- R-DA-EPOCH, R-CEOP90
- Where
- China
- Volunteers
- 475 people
- Sponsor
- Fujian Medical University
Tuberculosis
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
Background: Most people with tuberculosis (TB) feel better after starting treatment. But for some people, the opposite happens. They may feel better at first, but then suddenly get worse. This is a paradoxical reaction.
- Trial name
- NCT04052022
- Where
- 3 sites in United States, Mexico
- Volunteers
- 140 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Primary Sjögren's Syndrome
The ASSESS National Multi-center Prospective Cohort
The ASSESS national multi-center prospective cohort (Assessment of Systemic complications (Signs) and Evolution in Sjögren's Syndrome "SS") was set up in 2006 thanks to a grant of the French Ministry of Health.
- Trial name
- ASSESS (NCT03040583)
- Testing
- No intervention
- Where
- France
- Volunteers
- 395 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Auto-immune Diseases, Quality of Life
Auto-immune Diseases and Quality of Life
Systemic lupus erythematous (SLE), systemic sclerosis (Ssc) and inflammatory myopathy (IM) are rare diseases, whose prevalence is estimated at 43, 15 and 10 cases, respectively, for 100 000 inhabitants in France.
- Trial name
- QUALIMAIRAU (NCT02855840)
- Testing
- completion of the quality of life questionnaire
- Where
- France
- Volunteers
- 77 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Healthy Volunteers
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors [AI] (test) versus dual-chamber syringes [DCS] (reference) under controlled conditions in healthy adult…
- Trial name
- NCT05405985
- Testing
- Nemolizumab
- Where
- 2 sites in United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Multiple Sclerosis
Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group
The investigators want to evaluate ovarian reserve concerning patients with multiple sclerosis, compared to a control group of healthy women. This study will include women from 25 to 35 years old.
- Trial name
- FEMINISEP (NCT05754593)
- Testing
- Anti-Mullerian hormone (AMH) level, Antral follicle count (AFC), Clinical assessment
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Rheumatoid Arthritis
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
- Trial name
- NCT04171414
- Testing
- CT-P17 SC AI (adalimumab)
- Where
- Poland
- Volunteers
- 62 people
- Sponsor
- Celltrion
NHL, Non Hodgkin Lymphoma
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or…
- Conditions
- NHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT04555811
- Testing
- FT596, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Immune Thrombocytopenia
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
The primary objective of this study was to assess the long-term safety of lusutrombopag in the treatment of adults with relapsed persistent or chronic ITP with or without prior splenectomy.
- Trial name
- NCT01129024
- Testing
- Lusutrombopag
- Where
- 19 sites in United States
- Volunteers
- 19 people
- Sponsor
- Shionogi
Systemic Lupus Erythematosus
Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects
This is an open-label, randomized, parallel group, single dose study in healthy Chinese subjects. The purpose of this study is to characterize the pharmacokinetic profile and safety profile of 200 mg single dose of belimumab…
- Trial name
- NCT04136145
- Testing
- Belimumab for IV, Belimumab for SC
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
- Conditions
- Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
- Trial name
- NCT03628612
- Testing
- AUTO CAR T cell therapy
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 500 people
- Sponsor
- Autolus Limited
Paraneoplastic Neurological Syndrome, Autoimmune Encephalitis
New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis.
- Trial name
- DeNobio (NCT05728931)
- Testing
- Test of biological samples
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Hospices Civils de Lyon
Rheumatoid Arthritis
Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis (AutoDECRA)
This is a study which will look at safety, feasibility and acceptability of a new therapy called tolerogenic dendritic cells (TolDC), derived from the patient's own white blood cells, which will be injected into the knee joints…
- Trial name
- AutoDECRA (NCT01352858)
- Testing
- TolDC, Arthroscopy & saline irrigation alone
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Newcastle University
Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma
BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of BUCY+VP-16 and BUCY myeloablative conditioning regimens in diffuse large B-cell lymphoma undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma, Conditioning
- Trial name
- NCT03229616
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Rheumatoid Arthritis, Osteoarthritis
Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments
B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome
- Trial name
- NCT01642706
- Where
- France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Sars-CoV2, Chronic Inflammatory Rheumatism
Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases
Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge.
- Conditions
- Sars-CoV2, Chronic Inflammatory Rheumatism, Autoimmune Diseases
- Trial name
- covid19 fai2r (NCT04353609)
- Where
- France
- Volunteers
- 13,770 people
- Sponsor
- University Hospital, Lille
Rheumatoid Arthritis
Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The primary objective of the study is to evaluate the safety and tolerability of 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with active Rheumatoid Arthritis despite methotrexate therapy.
- Trial name
- NCT00425321
- Testing
- RWJ-445380 100 mg, RWJ-445380 200 mg, RWJ-445380 300 mg
- Where
- 42 sites in United States, Argentina and 5 more
- Volunteers
- 259 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.